在一个患有多重耐药性多细胞血病和双重JAK2基因突变的年轻患者中使用Ropeginterferon alfa-2b治疗:一个病例报告
Silvio Ligia1, Emilia Scalzulli1, Ida Carmosino1
1Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.
Frontiers in oncology
|January 24, 2024
概括
本病例报告详细介绍了一名患有多细胞血病 (PV) 的年轻患者,他受益于Ropeginterferon alfa-2b. 该研究强调了管理罕见JAK2突变的PV,并通过新型疗法改善了结果.
科学领域:
- 血液学 血液学 血液学
- 遗传学 遗传学是一种遗传学.
- 在瘤学瘤学.
背景情况:
- 血清多细胞 (PV) 是一种骨髓增殖性新生体,其特征是红细胞的过度产生.
- 由于疾病的复杂性和长期治疗考虑,儿科PV的管理存在独特的挑战.
研究的目的:
- 报告一个罕见的儿科多细胞血病真实病例,具有双重JAK2突变.
- 评估Ropeginterferon alfa-2b在患有耐火性PV的年轻患者中的疗效.
主要方法:
- 一个3岁的女性在2001年被诊断出患有PV的案例报告.
- 审查患者的血液学参数,治疗史和基因组分析.
- 对2023年开始的Ropeginterferon alfa-2b治疗的反应评估.
主要成果:
- 患者呈现出多细胞血症,高白血细胞症,血栓细胞症,壮症和腹部疼痛.
- 基因组分析显示了JAK2 V617F和一个罕见的JAK2 G301R突变.
- 罗佩基干扰素α-2b治疗导致了血液学参数的改善和症状的消失.
结论:
- 儿科PV管理可能是复杂的,特别是在额外的遗传突变.
- 罕见的JAK2突变的存在可能会影响疾病的严重程度和治疗结果.
- 在具有挑战性的PV病例中,Ropeginterferon alfa-2b显示出作为一种有效的治疗选择,以实现更好的疾病控制的潜力.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Bone Marrow Sampling and Transplants
331
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
331


